BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals logoBioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: BCRX
  • CUSIP: 09058V10
Key Metrics:
  • Previous Close: $6.12
  • 50 Day Moving Average: $6.17
  • 200 Day Moving Average: $5.19
  • 52-Week Range: $1.74 - $7.56
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.01
  • P/E Growth: -0.36
  • Market Cap: $451.40M
  • Outstanding Shares: 73,758,000
  • Beta: 3.67
Profitability:
  • Net Margins: -313.02%
  • Return on Equity: -296.19%
  • Return on Assets: -68.58%
Debt:
  • Debt-to-Equity Ratio: 6.35%
  • Current Ratio: 1.25%
  • Quick Ratio: 1.21%
Additional Links:
Companies Related to BioCryst Pharmaceuticals:

Analyst Ratings

Consensus Ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) (?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $8.00 (31.15% upside)

Analysts' Ratings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Show:
DateFirmActionRatingPrice TargetDetails
2/16/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$11.00View Rating Details
2/13/2017Piper Jaffray CompaniesReiterated RatingOverweight$8.00View Rating Details
1/23/2017FBR & CoReiterated RatingOutperformView Rating Details
12/16/2016JMP SecuritiesUpgradeMarket Perform -> Outperform$10.00View Rating Details
11/8/2016HC WainwrightReiterated RatingBuyView Rating Details
8/5/2016J P Morgan Chase & CoReiterated RatingHoldView Rating Details
8/5/2016Jefferies Group LLCBoost Price TargetHold$2.00 -> $3.00View Rating Details
2/26/2016Noble FinancialReiterated RatingBuy$8.00View Rating Details
2/9/2016Rodman & RenshawLower Price TargetBuy$24.00 -> $10.00View Rating Details
2/8/2016Needham & Company LLCDowngradeBuy -> HoldView Rating Details
11/11/2015Bank of America CorpDowngradeNeutral -> Underperform$12.00 -> $10.00View Rating Details
11/10/2015Oppenheimer Holdings, Inc.Reiterated RatingMarket PerformView Rating Details
8/10/2015MLV & Co.Reiterated RatingBuy$15.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2017        
11/7/2016Q316($0.24)($0.16)$5.94 million$7.80 millionViewListenView Earnings Details
8/4/2016Q216($0.26)($0.22)$3.92 million$4.80 millionViewN/AView Earnings Details
5/5/2016Q116($0.23)($0.31)$5.42 million$4.82 millionViewN/AView Earnings Details
2/23/2016Q415($0.26)($0.25)$6.34 million$4.60 millionViewListenView Earnings Details
11/5/2015Q315($0.20)($0.20)$6.77 million$11.00 millionViewListenView Earnings Details
8/7/2015Q215($0.22)$0.06$7.10 million$25.80 millionViewListenView Earnings Details
5/8/2015Q115($0.24)($0.21)$4.30 million$6.80 millionViewListenView Earnings Details
2/18/2015Q414($0.21)($0.16)$3.64 million$5.40 millionViewListenView Earnings Details
11/6/2014Q314($0.20)($0.12)$2.11 million$3.20 millionViewListenView Earnings Details
8/5/2014Q214($0.19)($0.23)$2.32 million$1.50 millionViewN/AView Earnings Details
5/8/2014Q114($0.17)($0.17)$3.34 million$3.50 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.09)$8.81 million$10.60 millionViewN/AView Earnings Details
11/5/2013Q313($0.14)($0.14)$2.01 million$2.40 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.14)($0.23)$2.01 million$0.82 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.15)($0.09)$1.31 million$3.60 millionViewN/AView Earnings Details
2/19/2013Q4 2012($0.16)($0.22)$4.02 million$4.10 millionViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.19)$4.63 million$5.80 millionViewN/AView Earnings Details
8/2/2012($0.26)($0.25)ViewN/AView Earnings Details
5/7/2012($0.26)($0.13)ViewN/AView Earnings Details
2/16/2012($0.33)($0.29)ViewN/AView Earnings Details
11/2/2011($0.30)($0.32)ViewN/AView Earnings Details
8/4/2011($0.26)($0.36)ViewN/AView Earnings Details
5/4/2011($0.20)($0.29)ViewN/AView Earnings Details
2/10/2011($0.21)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Current Year EPS Consensus Estimate: $-0.92 EPS
Next Year EPS Consensus Estimate: $-0.87 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.24)($0.20)($0.23)
Q2 20165($0.25)($0.17)($0.22)
Q3 20163($0.26)($0.22)($0.24)
Q4 20163($0.39)($0.21)($0.28)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Insider Ownership Percentage: 5.80%
Institutional Ownership Percentage: 76.88%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/19/2016Thomas R Staab IIInsiderSell3,250$7.45$24,212.50View SEC Filing  
9/14/2016Alane P BarnesVPSell8,357$4.27$35,684.39View SEC Filing  
8/25/2016Yarlagadda S BabuVPSell30,000$4.06$121,800.00View SEC Filing  
8/16/2016Bros. Advisors Lp BakerMajor ShareholderSell4,046,590$5.00$20,232,950.00View SEC Filing  
8/12/2016Thomas R Staab IIInsiderSell5,864$5.18$30,375.52View SEC Filing  
8/9/2016Thomas R Staab IIInsiderSell14,577$4.43$64,576.11View SEC Filing  
1/28/2016Bros. Advisors Lp Bakermajor shareholderBuy88,345$6.95$613,997.75View SEC Filing  
1/22/2016Bros. Advisors Lp Bakermajor shareholderBuy106,800$7.28$777,504.00View SEC Filing  
1/20/2016Bros. Advisors Lp Bakermajor shareholderBuy52,695$6.87$362,014.65View SEC Filing  
1/19/2016Bros. Advisors Lp Bakermajor shareholderBuy92,200$7.12$656,464.00View SEC Filing  
1/15/2016Bros. Advisors Lp Bakermajor shareholderBuy200,000$7.46$1,492,000.00View SEC Filing  
12/21/2015Thomas R Staab IICFOSell3,052$10.86$33,144.72View SEC Filing  
12/17/2015Thomas R Staab IICFOSell3,000$10.49$31,470.00View SEC Filing  
7/20/2015Thomas R Staab IICFOSell3,500$16.50$57,750.00View SEC Filing  
6/22/2015Thomas R Staab IICFOSell3,750$16.00$60,000.00View SEC Filing  
6/19/2015Alane P BarnesVPSell3,000$15.00$45,000.00View SEC Filing  
6/19/2015Jon P StonehouseCEOSell20,000$15.02$300,400.00View SEC Filing  
6/19/2015Thomas R Staab IICFOSell16,375$14.36$235,145.00View SEC Filing  
6/19/2015William P SheridanCMOSell70,389$15.05$1,059,354.45View SEC Filing  
6/5/2015Thomas R Staab IICFOSell6,000$12.75$76,500.00View SEC Filing  
5/18/2015Thomas R Staab IICFOSell3,000$11.00$33,000.00View SEC Filing  
3/19/2015Yarlagadda S BabuVPSell12,105$10.16$122,986.80View SEC Filing  
3/5/2015Yarlagadda S BabuVPSell37,400$10.59$396,066.00View SEC Filing  
3/4/2015Yarlagadda S BabuVPSell10,495$10.50$110,197.50View SEC Filing  
2/20/2015Nancy J HutsonDirectorBuy10,000$10.27$102,700.00View SEC Filing  
12/30/2014William P SheridanCMOSell128,399$12.36$1,587,011.64View SEC Filing  
12/29/2014Thomas R Staab IICFOSell9,500$12.56$119,320.00View SEC Filing  
12/29/2014William P SheridanCMOSell105,295$12.43$1,308,816.85View SEC Filing  
8/27/2014Thomas R Staab IICFOSell10,000$13.58$135,800.00View SEC Filing  
7/1/2014Thomas R Staab IICFOSell3,125$13.00$40,625.00View SEC Filing  
6/23/2014Thomas R Staab IICFOSell3,125$12.49$39,031.25View SEC Filing  
6/17/2014Thomas R Staab IICFOSell3,125$12.00$37,500.00View SEC Filing  
3/14/2014Thomas Staab IICFOSell3,125$11.24$35,125.00View SEC Filing  
3/6/2014Kenneth Lee, Jr.DirectorSell12,665$12.69$160,718.85View SEC Filing  
11/12/2013George AbercrombieDirectorBuy3,000$6.19$18,570.00View SEC Filing  
8/1/2013Felix BakerMajor ShareholderBuy1,136,364$4.40$5,000,001.60View SEC Filing  
3/5/2013George B AbercrombieDirectorBuy3,000$1.23$3,690.00View SEC Filing  
12/14/2012Peder JensenDirectorBuy20,000$1.51$30,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for BioCryst Pharmaceuticals (NASDAQ:BCRX)
DateHeadline
News IconBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Daily Sentiment Score At 0.054 - Stock Observer (NASDAQ:BCRX)
www.thestockobserver.com - February 21 at 11:28 AM
News IconAnalyst Views on Price Target: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Post Registrar (NASDAQ:BCRX)
postregistrar.com - February 21 at 11:28 AM
News IconStock Price of BioCryst Pharmaceuticals, Inc. (BCRX) Increases 15.9% - Highland Mirror (NASDAQ:BCRX)
www.highlandmirror.com - February 21 at 11:28 AM
capitalcube.com logoBioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : February 17, 2017 (NASDAQ:BCRX)
us.rd.yahoo.com - February 17 at 6:17 PM
finance.yahoo.com logoCoverage initiated on BioCryst Pharma by Ladenburg Thalmann (NASDAQ:BCRX)
finance.yahoo.com - February 16 at 8:57 PM
finance.yahoo.com logoCoverage initiated on BioCryst Pharma by Ladenburg Thalmann (NASDAQ:BCRX)
finance.yahoo.com - February 16 at 8:57 PM
News IconNotable Thursday Option Activity: BCRX, AXDX, HUM (NASDAQ:BCRX)
www.stockoptionschannel.com - February 16 at 3:56 PM
benzinga.com logoLadenburg Thalmann On Biotech: Buy BioCryst, Albireo Shares (NASDAQ:BCRX)
www.benzinga.com - February 16 at 3:56 PM
News IconUpside Visualized on BioCryst Pharma (BCRX); Sudden Bullish Activity for XTL Biopharma (XTLB) (NASDAQ:BCRX)
galaxystocks.com - February 16 at 3:56 PM
News IconIndicator Level Summary for BioCryst Pharmaceuticals Inc. (BCRX) - BVN (NASDAQ:BCRX)
bvnewsjournal.com - February 14 at 8:32 PM
News IconBioCryst Pharmaceuticals, Inc. (BCRX) stock trades up, “Overweight” rating reaffirmed by Piper Jaffray Companies ... - The Ledger Gazette (NASDAQ:BCRX)
ledgergazette.com - February 14 at 8:32 PM
News IconBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Daily Sentiment Score At 0 - Stock Observer (NASDAQ:BCRX)
www.thestockobserver.com - February 13 at 4:24 PM
News IconShares to Watch: Indicator Update on BioCryst Pharmaceuticals Inc. (BCRX) - Baldwin Journal (NASDAQ:BCRX)
baldwinjournal.com - February 13 at 4:24 PM
News IconShares in Review: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Benton Bulletin (NASDAQ:BCRX)
bentonbulletin.com - February 10 at 4:27 PM
News IconBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Quarterly Sales Review - The Newburgh Press (NASDAQ:BCRX)
newburghpress.com - February 3 at 4:02 PM
News IconEuropean drug agency to review BioCryst flu treatment (NASDAQ:BCRX)
wraltechwire.com - January 31 at 4:04 PM
capitalcube.com logoBioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BCRX-US : January 31, 2017 (NASDAQ:BCRX)
www.capitalcube.com - January 31 at 4:04 PM
News IconEuropean agency will review BioCryst’s flu drug (NASDAQ:BCRX)
www.heraldsun.com - January 30 at 4:55 PM
streetinsider.com logoBioCryst Pharma (BCRX) Says EMA Accepts Peramivir MAA Filing (NASDAQ:BCRX)
www.streetinsider.com - January 30 at 4:55 PM
us.rd.yahoo.com logoBioCryst Announces the Acceptance of Peramivir MAA Filing by the European Medicines Agency (NASDAQ:BCRX)
us.rd.yahoo.com - January 30 at 4:55 PM
us.rd.yahoo.com logo6:46 am BioCryst Pharma announces that the EMA has accepted the filing of its peramivir MAA for treatment of symptoms typical of influenza in adults 18 years and older (NASDAQ:BCRX)
us.rd.yahoo.com - January 30 at 4:54 PM
bizjournals.com logoBioCryst plans for European launch of injectable flu therapy (NASDAQ:BCRX)
www.bizjournals.com - January 30 at 4:54 PM
News IconChart Indicators in Focus for BioCryst Pharmaceuticals Inc. (BCRX) - Rives Journal (NASDAQ:BCRX)
rivesjournal.com - January 28 at 8:51 PM
News IconStock Perspective: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Earnings in View - Aiken Advocate (NASDAQ:BCRX)
aikenadvocate.com - January 27 at 10:21 PM
News IconQuarterly EPS Of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Set At $-0.21 - Stock Observer (NASDAQ:BCRX)
www.thestockobserver.com - January 27 at 10:21 PM
News IconInvestor Corner: Checking in on Shares of BioCryst Pharmaceuticals Inc. (BCRX) - Sherwood Daily (NASDAQ:BCRX)
sherwooddaily.com - January 26 at 9:30 PM
News IconBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Bearish Target At ... - Stock Observer (NASDAQ:BCRX)
www.thestockobserver.com - January 26 at 4:30 PM
nasdaq.com logoIs the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock? - Nasdaq (NASDAQ:BCRX)
www.nasdaq.com - January 26 at 4:30 PM
finance.yahoo.com logoIs the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock? (NASDAQ:BCRX)
finance.yahoo.com - January 25 at 4:05 PM
marketnewsvideo.com logoNotable Tuesday Option Activity: COF, BCRX, CRUS (NASDAQ:BCRX)
www.marketnewsvideo.com - January 24 at 4:21 PM
News IconBaker Bros Advisors LP Has Trimmed Its Holding in Biocryst Pharmaceuticals INC (BCRX) as Stock Price Rose (NASDAQ:BCRX)
randolphguide.com - January 24 at 4:21 PM
marketnewsvideo.com logoCommit To Buy BioCryst Pharmaceuticals At $3, Earn 52.5% Annualized Using Options (NASDAQ:BCRX)
www.marketnewsvideo.com - January 23 at 4:13 PM
capitalcube.com logoBioCryst Pharmaceuticals, Inc. – Value Analysis (NASDAQ:BCRX) : January 23, 2017 (NASDAQ:BCRX)
www.capitalcube.com - January 23 at 4:13 PM
News IconCCI Level Check for BioCryst Pharmaceuticals Inc. (BCRX) - Sherwood Daily (NASDAQ:BCRX)
sherwooddaily.com - January 22 at 8:51 PM
News IconBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Daily Sentiment Score At -0.39 - Stock Observer (NASDAQ:BCRX)
www.thestockobserver.com - January 22 at 8:51 PM
News IconMA Watch on Shares of BioCryst Pharmaceuticals Inc. (BCRX) - Rives Journal (NASDAQ:BCRX)
rivesjournal.com - January 21 at 2:58 AM
News IconStock Update on Earnings & Estimates for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Aiken Advocate (NASDAQ:BCRX)
aikenadvocate.com - January 21 at 2:58 AM
News IconBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Quarterly EPS Set At $-0.21 - Stock Observer (NASDAQ:BCRX)
www.thestockobserver.com - January 21 at 2:58 AM
capitalcube.com logoBioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : January 20, 2017 (NASDAQ:BCRX)
www.capitalcube.com - January 20 at 4:54 PM
capitalcube.com logoETFs with exposure to BioCryst Pharmaceuticals, Inc. : January 20, 2017 (NASDAQ:BCRX)
www.capitalcube.com - January 20 at 4:54 PM
News IconIndicator Level Review for BioCryst Pharmaceuticals Inc. (BCRX) - Sherwood Daily (NASDAQ:BCRX)
sherwooddaily.com - January 20 at 3:05 AM
News IconWill The Needle Move For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:BCRX)
wsbeacon.com - January 17 at 9:40 AM
nasdaq.com logoNoteworthy Friday Option Activity: TMUS, GME, BCRX (NASDAQ:BCRX)
www.nasdaq.com - January 13 at 4:30 PM
seekingalpha.com logoBioCryst Pharmaceuticals (BCRX) Presents At 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:BCRX)
seekingalpha.com - January 11 at 9:18 PM
News IconStock Reaching Most Volatile List Today: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Wall Street Beacon (NASDAQ:BCRX)
wsbeacon.com - January 11 at 4:11 PM
News IconBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) hit its 52 Week ... - The Newburgh Press (NASDAQ:BCRX)
newburghpress.com - January 11 at 4:11 PM
News IconTrader's Buzzer: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ... - Post Registrar (NASDAQ:BCRX)
postregistrar.com - January 10 at 3:58 PM
marketexclusive.com logoBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Files An 8-K Regulation FD Disclosure - Market Exclusive (NASDAQ:BCRX)
marketexclusive.com - January 10 at 2:58 AM
finance.yahoo.com logo3:38 am BioCryst Pharma receives approval for RAPIVAB in Canada (NASDAQ:BCRX)
finance.yahoo.com - January 9 at 4:56 PM
biz.yahoo.com logoBIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:BCRX)
biz.yahoo.com - January 9 at 4:56 PM

Social

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

Where is BioCryst Pharmaceuticals' stock going? Where will BioCryst Pharmaceuticals' stock price be in 2017?

8 equities research analysts have issued 12 month target prices for BioCryst Pharmaceuticals' stock. Their predictions range from $3.00 to $11.00. On average, they expect BioCryst Pharmaceuticals' stock price to reach $8.00 in the next twelve months.

When will BioCryst Pharmaceuticals announce their earnings?

BioCryst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.

Who owns BioCryst Pharmaceuticals stock?

BioCryst Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include RTW Investments LP (5.53%), Deerfield Management Co. (4.39%), State Street Corp (2.84%), Perceptive Advisors LLC (1.80%), FMR LLC (1.00%) and Royce & Associates LP (0.20%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Bros Advisors Lp Baker, Jon P Stonehouse, Thomas R Staab II, William P Sheridan and Yarlagadda S Babu.

Who sold BioCryst Pharmaceuticals stock? Who is selling BioCryst Pharmaceuticals stock?

BioCryst Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Co., RTW Investments LP, Royce & Associates LP, Metropolitan Life Insurance Co. NY and National Planning Corp. Company insiders that have sold BioCryst Pharmaceuticals stock in the last year include Alane P Barnes, Bros Advisors Lp Baker, Thomas R Staab II and Yarlagadda S Babu.

Who bought BioCryst Pharmaceuticals stock? Who is buying BioCryst Pharmaceuticals stock?

BioCryst Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, State Street Corp, FMR LLC, Renaissance Technologies LLC, Two Sigma Investments LP, Trexquant Investment LP, Ellington Management Group LLC and Federated Investors Inc. PA.

How do I buy BioCryst Pharmaceuticals stock?

Shares of BioCryst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of BioCryst Pharmaceuticals stock cost?

One share of BioCryst Pharmaceuticals stock can currently be purchased for approximately $6.10.

BioCryst Pharmaceuticals (NASDAQ:BCRX) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Earnings History Chart

Earnings by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Dividend History Chart

Dividend Payments by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Last Updated on 2/22/2017 by MarketBeat.com Staff